In a major development, Orexa B.V., a Dutch life sciences company dedicated to advancing medical solutions, proudly announces the initiation of its Phase 2 clinical trial aimed at preventing postoperative ileus. The trial marks a crucial step forward in understanding whether Orexa's innovative medicine, ORE-001, can mitigate gastrointestinal disturbances and expedite recovery for patients undergoing major abdominal surgery.

The study is a meticulously designed multi-centre endeavour and a randomised, double-blind, and placebo-controlled investigation. The trial seeks to enrol 100 to 120 female patients undergoing gynecologic surgery requiring longitudinal laparotomies.

Distinguished medical centres across Germany are actively participating, with Professor Alexander Mustae from Universitätsklinikum Bonn (UKB) leading the research efforts. The inaugural patient received their first dose on January 11, 2024, in Bonn, marking a significant stride in medical research.

Professor Ard Peeters, expressing enthusiasm, states, "Initiating our first clinical Phase 2 study is a monumental achievement for Orexa. This study is especially crucial as we focus on a patient group where we can potentially prevent postoperative ileus—a serious complication affecting up to 50% of patients in various groups. By addressing this issue, we aim to enhance patient recovery, reduce hospitalisation durations, and ultimately improve overall healthcare outcomes."

Orexa's lead compound, ORE-001, holds promise for revolutionising postoperative care, and the company's dedication to advancing medical science is evident in this groundbreaking trial. As Orexa takes this leap forward, the potential impact on patient well-being is substantial, with hopes for a brighter and healthier future.